European Medicines Agency gives green light to first meningitis B vaccine
Clinical The first vaccine against the most common form of meningitis could soon be licensed for use in the UK, following a recommendation for approval from the EMA. Meningitis UK hailed the move as “a landmark moment in the fight against meningitis”
The first vaccine to protect against meningitis B could soon be licensed for use in the UK, following a recommendation for approval from the European Medicines Agency (EMA).
The EMA issued a positive opinion for the 4CMenB vaccine (Bexsero) last week and the European Commission will give its verdict in the next three months.
|
More on vaccination
|
Babies to get rotavirus vaccinationThe vaccine, manufactured by Novartis, has been recommended for use in those aged two months and older, and would be the first to protect against the most common form of meningitis.
4CMenB is under consideration by the Joint Committee for Vaccination and Immunisation for inclusion on the UK national immunisation programme.
Meningitis UK hailed the EMA recommendation as "a landmark moment in the fight against meningitis" and said it would be "campaigning hard" to ensure the government introduced it to the immunisation schedule.
|
Do you think the government should add the jab to the national immunisation schedule? Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook |
